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Abstract. The first trial applications of Contrast-Enhanced Synchrotron Stereotac-
tic Radiation Therapy (SSRT) is underway since June 2012 at the European Syn-
chrotron Radiation Facility (ESRF) in Grenoble (France). The phase I-II clinical trial
is designed to test the feasibility and safety of SSRT through a dose escalation pro-
tocol. Contrast enhanced radiotherapy achieves localized dose enhancement due to
higher photoelectric effect rate in the target. This increase is obtained through the
preferential uptake of high-Z media (iodine) in the tumoral area combined with irradi-
ations with medium energy synchrotron X-rays. In vivo dosimetry (i.e. experimental
dosimetry in real time during the treatment) would be a serious added value to the
project, in terms of online dose monitoring and quality control. It is challenging to
perform in vivo dosimetry with the currently available conventional clinical techniques.
In this work we investigated a method using X-ray fluorescence detection to derive the
iodine concentration contained in a tumor during the treatment of a patient, as a first
step towards in vivo dosimetry. A mean iodine concentration of 0.33 ± 0.22 mg/ml
has been retrieved in the tumor of the patient compared to 2 mg/ml expected would
correspond to 3% local dose enhancement in the tumor. Further work will be per-
formed to improve the attenuation correction method. The expected amount of iodine
should be 2 mg/ml in the tumor (20% dose enhancement). This method is suitable
to detect iodine in the target but has some problem in quantifying the real amount of
iodine present during the irradiation.
This study takes place within the scope of phase I/II clinical trials of Stereotactic
Synchrotron Radiation Therapy (SSRT). The trial is designed to prove the feasability
and safety of SSRT through a dose escalation protocol. The patients who benefits from
this modality suffer from brain metastasis of medium to small volume.
SSRT consists in loading a tumor with an iodinated contrast agent (CA) through
intraveneous injections. The CA selectively leaches into the tumor because of the
localised blood brain barrier (BBB) permeabilisation [1]. The impaired BBB and hence
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2iodine biodistribution is directly related to the tumor presence. Moreover the iodine
is located in the interstitial space and in the vessels so the dose will be delivered to
the target cells and neovasculature, under the assumption of an homogeneous emission
of the secondary particle. [2]. The combination of CA and a stereotactic irradiation
with mono-energetic kilovoltage X-rays produces a gradient in the absorption cross-
section leading to an increased dose deposition [3]. A differential effect is produced
between the tumor and the healthy brain depending on the iodine uptake, leading to
a difference in the photon interaction mechanisms. The photoelectrons produced in
the target volume deposit their energy over a sub-millimetric distance in the vicinity
of heavy atoms, whereas Compton scattering predominates in the surrounding healthy
tissues. As a consequence, the dose deposition upstream and downstream the tumor
is further reduced while the dose in the tumoral tissue is reinforced. This differential
effect is a substential added value to the high energy treatments performed nowadays.
Robar et al studied the use of iodine as a radiosensitizer in conventional SRT (energy
beam ranging from 2 MV to 18 MV) and reported a dose enhancement factor (DEF)
for iodine concentration around 3 mg/ml of iodine of less than 1.6 % [4]. On the other
hand Edouard et al reported a DEF of 10% per mg/ml of iodine during the SSRT
treatment [5]. At high energy, the DEF is then negligible, hence the necessity of using
a low-medium energy x-ray source. In order to achieve a satisfying DEF a synchrotron
source is not mandatory, only the photon energy matters. A first clinical trial performed
in the 90’s [6] used a modified X-ray tube and presented a total treatment time of 45
minutes (3x15 mins with cooling periods in between) because of the need of cooling
down the x-ray tube. However, a synchrotron offers significant advantages compared
to a conventional x-ray tube, in offering tunable monochromatic high flux x-ray beam,
and a substantial reduction of the treatment time (20 mins including positioning), and
the optimal energy between high DEF and low dose to the bone can be chosen. [5] The
iodine injection is thus only used for the SSRT fraction of the treatment.
There is a linear relationship between the localized dose enhancement and the iodine
concentration, as shown by [7]. A localized 10% increase per mg/ml is achieved in the
tumor when compared to an irradiation at the same energy, without contrast agent. The
treatment planning system is taking the iodine presence into account for the calculation
(Monte Carlo based treatment planning system) As well as radiotherapy programs,
innovative X-ray imaging techniques using the inherent properties of synchrotron
radiation such as the high photon flux density, the broad energy spectrum, the natural
collimation and the linear polarization are under active developement.
Fluorescence spectroscopy is commonly used to detect low contents of specific heavy
atomic number elements in material science. Until now fluorescence hadn’t been
used to assess the iodine concentration and its resulting dose enhancement. Applying
this technique to medical imaging, it becomes conceivable to track down the iodine
uptake of an organ without the low sensitivity of conventional CT acquisitions [8].
The measurement of the distribution of iodine within the thyroid gland [9] has been
made using Fluorescence X-ray Computed Tomography (FXCT) [10]. Later in 2005 the
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3cerebral perfusion of a living mouse has been retrieved using FXCT [11]. Nevertheless,
FXCT is not appropriate for the purpose of SSRT for reasons linked to the irradiation
time, and scale problems due to the brain and skull thicknesses in human. Moreover, the
small detection volume in the detector makes the measurement of fluorescence X-rays a
rare event due to small detection solid angle, so compromise between spatial resolution
and measurement’s statistical reliability has to be found.
During SSRT treatment, the irradiated iodine atoms emit characteristic X-rays (Kα
line at 28.5 keV) whose amount depends directly on the iodine concentration in the
tumor. The exact measurement of the tumor’s CA uptake would be a serious added
value in terms of on line dose monitoring and quality assurance. In any case, it should
be noted that the irradiation in SSRT consists on 3 to 10 weighted beams distributed
around the patient’s skull, which is an other reason why FXCT as commonly used is
not appropriate. The substantial thickness of tissue in human skull and the low number
of beams incidence are technical rationales sufficient to investigate a simpler alternative
to FXCT, in which 3D iodine average concentration can be retrieved.
Therefore the aim of this work is to examine the feasibility retrieving absolute iodine
concentration in real time during the SSRT treatment as a first step towards in
vivo dosimetry in SSRT. The feasability of fluorescence detection was examined by
preliminary Monte-Carlo simulations using the code PENELOPE (Penetration and
ENErgy LOss of Positrons and Electrons) involving an analytical human head phantom
as the geometry used for parametric study [7]. A calibration data of iodine content
was obtained from tubes filled with various concentrations of iodine and irradiated with
synchrotron monochromatic low-energy X-rays. A model was then developed to relate
the fluorescence rate detected to the iodine amount. Finally this model was used to
determine the average iodine concentration in patients tumors during treatments. This
is the first mandatory step to propose an in vivo dosimetry modality in SSRT.
1. Material and Methods
1.1. Monte-Carlo Simulation
The aim is to retrieve the signal generated by the Kα line of iodine which is at an average
energy of 28.5 keV composed of Kα1 (28.61 keV) and Kα2 (28.32 keV) and accounts for
about 85% of the lines produced after a K-shell ionisation [12], the other 15% are coming
from Auger emission. At these energies the average mass attenuation coefficient of the
brain tissue is around 0.3811 cm2/g (1.331 cm2/g for the skull,bone, ICRU-44 [13]). By
considering a tumor 5 cm in depth behind a skull of 1 cm thick, we can simply calculate
the amount of fluorescence that comes out from the head using the Beer-Lambert law
in a given direction. It is less than 0.05% of the fluorescence generated. Moreover, the
detector receives only photons emitted in a well defined solid angle which results in a
further fall of the count rate due to the isotropic fluorescence emission.
The environment of the tumor (brain, skull, skin) and its size enlarges the scat-
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4Figure 1. (a) Ellipsoid phantom used for the simulation (b) Iodine fluorescence signal
collected in a 3x3x1 mm3 CZT volume
tered photon rate which could in a sense worsen the signal to noise ratio (SNR). As a
consequence, the first point that is investigated is the feasability of the spectrometric
measurement in SSRT by the mean of Monte-Carlo simulations. For this purpose, the
Monte-Carlo code PENELOPE is used together with code PENGEOM to define geom-
etry files (bodies).
An analytical human head phantom is used, described by Bouchet & al [14] adapted
from nuclear medicine studies using the MIRD formalism. A tumor is modeled by a
cylinder (2 cm height, 2 cm diameter) filled with a homogeneous mixture of brain ma-
terial and iodine at various concentrations ranking from 0 to 20 mg/ml. The tumor
is positionned at the center of the brain as shown in Figure 1. The materials that fill
the bodies are adapted from the database of the ESTAR program of Berger [15] for the
brain, skull and skin. As far as mixtures and compounds are concerned, the weighted
sum method is adopted to define the material cross sections, which means that the
corresponding molecular cross section is set equal to the sum of atomic cross sections
weighted with the stoichiometric index of the element.
A small CdZnTe (CZT) cuboid of 3x3x1 mm3 is set as an energy deposition detector and
placed according to the x-axis. Finally, the simulated beam is a 2x2 cm2 square field, po-
larized, parallel and monochromatic at the energy of 80 keV emitting photons along the
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5Figure 2. Set up used for fluorescence measurement on patients. In case of the
acquisition of the calibration curve, tubes were not placed in head phantom.
y-axis to form a 90 degrees angle with the detector. The irradiation is performed in the
xy-plan and the number of photons simulated accounts for 109. Electron and photon
cut-of are both set at 25 keV as this value is lower than the Kα1 and Kα2 for iodine and
particles with such energy cannot produce fluorescence from the iodine K edge which is
of interest here. Coefficients C1 and C2 are both set at 0 for a fully detailed simulation
of the scattered radiation. The spectra obtained are then processed to simulate a real
spectrum acquired with a CZT detector [16]. This numerical treatment distributes a
certain amount of counts from the full energy peak at lower energy channels, and the
peak is enlarged as a Gaussian distribution. In other words, the procedure considers
the statistical spread in the number of charge carriers and charge collection phenomena.
The MC simulations are performed to evaluate the fluorescence detection feasibility in
a clinical case.
1.2. Analytical Model for Iodine Concentration Quantification
As the fluorescence rate depends on the iodine concentration, the volume irradiated, the
incident flux and the irradiation time, a calibration curve is realized to characterize the
iodine concentration in the tumor.
The set up used is basically an FXCT set up as described on Figure 2 with a Amptek
CZT detector with a detection volume of 3x3x1 mm3 placed at 90 degrees of the
incident beam and at 155.2 cm from the isocenter. This way of positioning the
fluorescence detector reduces the background from Compton scattering. This improves
the detectability of the fluorescence X-rays by taking advantage of the linear polarisation
of the synchroton beam [17]. A 2 millimeters pinehole is used to geometrically
select the photons coming from the isocenter and to reduce the amount of scattered
photons detected. Despite these collimation elements a significant aperture remains
and represents a circle of 15 cm in radius at the level of the isocenter.
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6Figure 3. Irradiation geometry used in the analytical modelling of the calibration
curve.
An array of solutions with concentrations varying from 0 to 20 mg/ml are prepared and
placed into cylindrical plastic tubes of 3 cm in diameter and 3 cm high. Absolute iodine
concentrations is derived from monochromatic computed tomography (CT) images of
the tubes using the subtraction of a CT image of a tube filled with pure water [18]. The
tubes are thus irradiated with a 2 mm thick beam at 80 keV using 2 irradiation modes,
static and bottom to top scanning with the same irradiation time. Finally, the spectrum
acquired are processed to remove the background from scattered photons using the 3
channels method [19] and to extract the fluorescence rate.
This simple experiment is also simulated using MatLab (MATLAB 9.1, The
MathWorks Inc., Natick, MA, 2000). The tube is divided into pixels 10 µm x 10 µm
(dx × dy) as shown of Figure 3. The emitted fluorescence fi,j in a given pixel Pi,j is
calculated with equation 1. If we assume an equal iodine concentration [I] for each pixel
of the target, the amount of fluorescence delivered by a given pixel Pi,j depends only
on the amount of pixels filled with iodine that the photon flux Φ impacts before the
interaction with the pixel emitter. This number multiplied by dx defines the depth Li,j
for each pixel Pi,j with regards to the entrance beam.
fi,j = τµpe80dx · Φe−µ80·Li,j (1)
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7Table 1. Irradiation/Simulation parameters
Φ 3 · 1012 ph/cm2/s
Beam width 3 cm
Beam height 2 mm
τ 0.8
Ω 3.18 · 10−7 sr
With τ the fluorescence yield of the Kα line of iodine µpe80 and µ80the linear attenuation
coefficient of the photoelectric effect at 80 keV for the solution in a given voxel, dx the
length of the pixel and total attenuation coefficient respectively, Φ the ESRF photon
fluence, Li,j the depth of the pixel Pi,j. Considering the distance Di,j of the emitted
fluorescence fi,j in the direction of the detector inside the tube, the detected fluorescence
is calculated using equation 2.
fdet(I) =
Ω
n
∑
i,j
fi,je
−µtot([I])
ρ
ρ·Di,j (2)
with µtot([I])
ρ
as the total linear attenuation coefficient of the iodine mixture calculated
in the diluted approximation solution using equation 3.
µtot([I])
ρ
=
[
µ
ρ
]
H2O
× (1− [I] · 10−3) +
[
µ
ρ
]
I
× [I] · 10−3 (3)
Where Ω the solid angle defined by the emitting pixel to the aperture of the detector,
n is the number of pixels in the tube. Using the irradiation parameters described by
Table 1. The results of the calculation are compared to the fluorescence measurement
to validate the calibration curve.
1.3. Measurement during patient treatment
The experimental set up is exactly the same as in the previous part (Figure 2). The
tumor of the patient is placed at the isocenter of the treatment room and the irradiation
is performed using several incidences (3 to 8 for the 3 patients studied here).
In order to maximise the spare of healthy tissue,every beam is shaped by a Cerobend
mask placed between the X-ray source and the patient, according to the limits of the Plan
Target Volume (PTV) plus a 3 mm margin. The fluorescence spectrums are acquired
for every beam incidences and processed to retrieve the iodine concentration in the
tumor. Figure 4 shows a print screen of the treatment plan used in SSRT and allows
the visualisation of the beam incidences.
Firstly, spectrums are filtered using a low pass filter in the Fourier space to remove
the statistical noise which is expressed through fast oscillations. Both the peak stripping
method and the 3 channels method are used to remove the background and return the
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8Figure 4. CT Scan extracted from the TPS. The tumor is irradiated with 8 weighted
beams (bottom right hand corner). The material segmentation (bottom left hand
corner) shows the ring shaped iodine uptake at the isocenter height.
same results. Peak stripping method is a way of spectrum calculation that detects peaks
and iteratively merges them to the background line [19]. As for the 3 channels method,
it geometrically adjusts a trapezium under the peak and removes it.
For the spectrum calculation only the 3 channels method is used because this
technique is the fastest.
In the general case, when the fluorescence rate is retrieved for each beam incidence, a
normalisation procedure sould be applied. The idea is that the total irradiated volume
is set by the Cerobend masks which shapes come directly from the TPS and is not
depending on the irradiation incidence. Therefore the iodinated irradiated volume
remains the same during the whole treatment. Retrieving the iodine concentration
in the tumor would require the normalization of the fluorescence rate to the same
irradiation conditions as the tubes in order to compare directly the fluorescence rate
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9in both cases. Such normalization should account for the irradiation time, the photon
flux which decreases with time and tissue attenuation. But in SSRT one can benefit
from the fact that each of the irradiation port delivers the same dose to the isocenter
(1
8
of 7Gy). One key aspect that is investigated is how the measured fluorescence varies
with the dose to the medium. In the case where the dependence is proportional,
the normalization to the incoming fluence becomes pointless and the only remaining
step between fluorescence measurement and iodine concentration retrieval is tissue
attenuation correction for 28.5 keV photons (Iodine’s Kalpha line). For this purpose,
a serie of MC simulations involving tubes 3 cm in diameter 3cm high filled with 5mg/ml
of iodinated solution and 1 cm thick slabs of brain material is used. The brain slabs are
positioned between the 80keV photon source and the tube. The brain thickness ranges
from 1 cm to 4 cm. In the mean time the same experiment is realized with a tube filled
with 5mg/ml of iodinated solution and brain slabs from the CIRS (CIRS, Norfolk, VA
,USA), radiosurgery phantom MODEl605.
The beam used for the imaging procedure is the same used for the treatment which is
a monoenergetic 80 keV beam. At the ESRF the tomography reconstruction algorithm
generates CT scans where pixel values are the linear attenuation coefficient at the
scanning energy.
Therefore, tissue attenuation correction for 28.5 keV photons is computed from a
patient specific CT scan realized between the iodine injection and the patient irradiation.
The resolution of the CT scan is 841x841 with a pixel size of 336×336 µm2 The
extrapolation of mass attenuation coefficient obtained on the CT image tothe value
required for 28.5 keV photons is calculated using the method described by Schneider &
al [20]. In this method the Hounsfield units (in our case the grey values of the image)
at a given energy of each material are sorted. Any in between Hounsfield unit present
in the image is then described as a mixture of the two elements matching two closest
material Hounsfield unit values. The mass attenuation coefficient at 28.5 keV from the
NIST database for each material is finally used to extrapolate the CT image at 28.5
keV.
For the purpose of this work 3 regions are defined. The first one is a mixture of
brain tissue and iodine. [8] has stated that a small amount of iodine remains in the
brain tumoral tissue after the injection so this segmentation is applied for Hounsfield
units close to the tumoral tissue. For regions close to the bone, materials are described
as a mixture of brain and spongy bone. The skull being a sequence of spongy bone
and cortical bone, any Hounsfield unit around the spongy bone value will be treated
as a mixture of spongy bone and cortical bone. The last region is treated as cortical
bone only. Figure 5 shows a profile from the 80 keV CT scan. The values of the linear
attenuation coefficient for each material is extracted from the NIST database. The
mixtures are calculated as a weighted sum of two materials. Considering µ1 and µ2
the linear attenuation coefficient at 80 keV from the NIST database of two materials
composing the mixture and α and β the mass fractions. Any µ1 < µib < µ2 in between
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10
Figure 5. Profile from the 80 keV CT scan. Distance 0 is at the isocenter and the
profile crosses the brain and the skull.
(ib) linear attenuation coefficient in the image be written as:{
µib = αµ1 + βµ2
1 = α + β
(4)
Solving the equation leads to:
{
β = µib−µ1
µ2−µ1
α = 1− β (5)
The coefficients α and β are then used for each pixels to attribute an extrapolated
value of the linear attenuation coefficient at 28.5 keV µe,28.5keV as given by equation 6
where are the linear attenuation coefficient of the materials at 28.5 keV from the NIST
database.
µe,28.5keV = αµ1,28.5 + βµ2,28.5 (6)
The linear attenuation coefficient used at 28.5 keV are µtot − µRayleigh. As a matter
of fact, including Rayleigh scattering in the linear attenuation coefficient means that a
photon that interact through Rayleigh mechanism will not be detected. The 15 cm in
radius aperture at the level of the isocenter makes Rayleigh photons detectable by the
CZT detector. The tissue attenuation is finally corrected using the extrapolated 28.5
keV CT scan. For each irradiation port the attenuation coefficient is calculated as the
mean coefficient in a cone from the isocenter and limited by the size of the active volume
area of the CZT detector which represents an average over 10 lines.
2. Results
Monte-Carlo Simulation
The Monte-Carlo simulations provides results that confirm the feasability of fluorescence
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detection in the case of a centered tumor. The mean concentration of iodine in the tumor
volume is expected to be around 1.95±0.12 mg/ml as measured on 12 patients by Obeid
& al [8]. For the simulation, a concentration of 5 mg/ml is used and leads to a SNR of
5.28 as shown in Figure 1. It is reasonably assumed that we can detect the iodine concen-
tration in real patient. Building a calibration curve from the Monte-Carlo simulation is
unrealistic because of the low statistics in the small detection volume (3x3x1 mm3). As
a consequence these simulations show that the detection of iodine on patients is feasible.
Calibration Curve
Results of the calibration are shown on Figure 6 for an irradiated volume of 1.14 cm3 and
a 1 second irradiation time. The model described in section 2.2 and the experimental
data agree within the error bars for concentrations ranking from 0 to 20 mg/ml.
The calibration curve is bended which is due to the fact that the water absorbs less the
photons than the iodine at a given energy. In the case of an equal absorption between the
matrix and the analite the fluorescence would have a linear dependance with the analite
concentration [19]. The simulated curve is slightly lower than the measured one as it
comes from a calculation that only accounts for the primary interactions. Scattered
radiation who’s influence depends on the photon spectrum and irradiation geometry
is not modelled here as its accurate quantification is not accessible analytically. The
mean difference between the simulated and measured fluorescence is 15% which might
correspond to the influence of the fluorescence emitted after interactions of scattered
radiation in the tube. This simulation also allows the visualisation of the relative
fluorescence intensity of each pixel and their contribution to the signal (Figure 7). It
should be noticed that the major part of the signal comes from pixels at the edge of
the tube in the direction of the detector and not from the isocenter. This is due to the
attenuation of the 80 keV photons inside the tube on one hand and self absorption of
28.5 keV photons within the medium combined with the irradiation geometry on the
other hand.
Measurement during patient treatment
Each spectrum acquired for each irradiation incidence is shaped like the spectrum
provided by Figure 8 which is the first one ever recorded in SSRT. The intensity of the
Kα line depends on the irradiation time and both the distances between the isocenter
and the beam entrance point (x1) and the isocenter to the exit point (x2).
The red curve on Figure 8 is the result of the numerical process to remove the scattered
radiation background. The correct fluorescence rate is extracted by fitting the peak
with a 2 Gaussians function. The 2 Gaussians function is more appropriate to describe
a photoelectric peak from a CZT detector because of its asymmetry due to incomplete
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Figure 6. Calibration curve obtained from irradiated tubes and calculated from the
model.
Figure 7. (a) Relative fluorescence isotropic emission intensity in the numerical
tube.(b) Relative contribution of each pixel to the measured signal.
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Figure 8. Spectrum detected for one irradiation incidence versus channel number.
The blue line is the raw spectrum and the red line is the iodine Kα line obtained with
background removal.
charge collection. The content of every channel is then summed to obtain for each
irradiation incidence the detected fluorescence rate.
In order to compare the fluorescence rate to the calibration curve, a normalisation
procedure has to be applied. In SSRT, each irradiation incidence deliver the same dose
to the isocenter. The results of the MC study about the assumption that the fluorescence
rate detected is proportional to the dose at the isocenter are shown on Figure 9. The
dose and the number of counts are normalised to the maximum measured for tubes
filled with 5mg/ml of iodine. The measured fluorescence and the dose calculated for
tubes filled with 5mg/ml follow the same trend as the brain thickness increases, i.e. the
detected fluorescence rate is proportional to the dose to the isocenter. In addition, when
normalising to the dose to water, the increase in dose deposition in a 5mg/ml tude is
around 50 percents which corresponds to values found in the litterature (10% increased
dose per mg/ml iodine) [8].
Thanks to this calculation, the normalisation procedure becomes easier, irradiation
parameters independent, but depends only on the patient geometry. The next step is
then to numerically remove the tissue around the tumor by exploiting the CT image
acquired with a 80keV monochromatic beam for centering the patient, and extrapolate
the mass attenuation coefficient to their value at 28.5 keV. The first attempt is realized
on tubes filled with 5mg/ml of iodine and the results are shown on the following table:
In this case of very simple geometry, the extrapolation of the Hounsfield units from a
80 keV CT scan to 28.5 keV allows retrieving the expected fluorescence rate. The brain
thickness removal produces fluorescence values in agreement with the data acquired on
Page 13 of 18 AUTHOR SUBMITTED MANUSCRIPT - BPEX-101000.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Ac
ce
pte
 M
an
us
cri
pt
14
Table 2. Fluorescence normalized to the machine current for a bare tube and corrected
for brain attenuation using extrapolation method.
Irradiation conditions Raw data /mA/s Corrected data
Bare Tube 52 ± 1.5% 52 ± 1.5%
Tube + 1cm brain 37.53 ± 1.8% 53.53 ± 1.8%
Tube + 2cm brain 25.53 ± 2% 51.60 ± 3%
Tube + 3cm brain 18.01 ± 2% 53.80 ± 3%
Tube + 2cm brain 13.72 ± 2% 51.85 ± 3%
Figure 9. Comparison between the dose to the isocenter of the tube calculated with
MC (solid line) in a 5 mg/ml iodine solution and the detected fluorescence rate (dashed
line). The doted line is the dose to water.
the bare tube within the error bars. Finally, the attenuation coefficient extrapolation is
tested on a CT scan from a real patient, performed after the irradiation. As described
in section 2.3 (Figure 4), the 80 keV CT scan is extrapolated to 28.5 keV to obtain a
map of linear attenuation coefficient at this energy. The tissue thickness is then removed
by acquiring pixels values on the lines from the isocenter to the detector and 10 other
adjacent lines which are representative of the aperture of the detector. Figure 10 dis-
plays the corrected fluorescence rate versus the irradiation incidence. The procedure is
supposed to produce the same number of counts for each irradiation port, but as shown
Page 14 of 18AUTHOR SUBMITTED MANUSCRIPT - BPEX-101000.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Ac
ce
pte
d M
an
us
cri
pt
15
on Figure 10, the difference between the calculated fluorescence for the incidence ports
can be up to a factor of 10.The additional source of uncertainties can be the detection
noise, the error made using the 3 channel method and the standard deviation over the
10 lines in the CT scan and varies between 4% and 15%.
Figure 10. Fluorescence rate retrieved for each irradiation incidence.
Table 3. Caption to table
Irradiation port [I]mg/ml ∆[I] mg/ml
1 0.102 ± 0.008
2 0.170 ± 0.025
3 0.605 ± 0.028
4 0.801 ± 0.034
5 0.430 ± 0.033
6 0.322 ± 0.019
7 0.073 ± 0.007
8 0.138 ± 0.013
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3. Discussion
The results of the MC combined with the analytical study highlight the fact that
the iodine fluorescence detection using a CZT detector is achievable. Previous studies [8]
found a mean iodine uptake for 5 patients of 1.54±0.19 for one protocol and 1.94±0.12
for an other. But in this case, the iodine uptake is not homogeneous and is ring shaped
around what appears to be a necrotic core (Figure 4). The signal coming from the edge
of the tumor may be averaged because the numerical procedure assumes an emission
from the isocenter and finally lowers the iodine concentration retrieval. Moreover, the
CT scan being acquired after the irradiation causes the iodine to be partially washed
out of the tumor.
The patient specific procedure based on the CT scan can be quantify using the
linear attenuation coefficient at 28.5 keV of brain and two types of bones (ICRU-44).[13]
Assuming an error of 10% on the extrapolation of both brain and skull attenuation
coefficient, one can calculate the error made once used in the Beer-Lambert law.
Considering a 1 cm thick brain slab and a 1 cm thick bone as a combination of 2×1mm
of cortical bone and 8mm of spongy bone, such error will lead respectively to 3.4%/cm
and 16%/cm in difference in the calculated fluorescence rate. It has also been pointed
out by Verhaegen et al that the uncertainty in the tissue composition could lead to
large errors in the dose deposition. Whereas the probability of the Compton effect for
different tissues depends only on the electron density, the probability of photoelectric
effects depends very strongly on the effective atomic number Z3−4 of the tissues [21].
The model used in this paper utilizes artificial mixtures that are correct for high energy
photon beams but leads to large fluctuations in the retrieved fluorescence rate because
the photoelectric effect is responsible for the fluorescence emission. As a consequence
the retrieved fluorescence is underestimated due to an overcorrection of the number
of photons when large bone thicknesses are involved. Despite difference in the
retrieved fluorescence rate, using the calibration curve previously obtained the iodine
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concentrations are in the range, between 0.1 mg/ml and 0.8 mg/ml(Table 3).
The major part of the uncertainties comes from the extrapolation procedure. In
the range of energies between 28.5 keV and 80 keV the difference in photon interaction
mechanism is huge for materials such as bones. Interfaces (brain/bone etc) are handled
by the mean of thresholds applied depending on the pixel values. Those thresholds
remain user dependant and can lead to differences in the results.
The improvement of the collimation should suppress the detection of fluorescence
photons from above and below the isocenter level, and increase the accuracy of the
correction based on one single CT slice at the isocenter level. One advantage of the
technique is that the calculation is instantaneous, which is an added value for real in
vivo detection.
4. Conclusion
This study is a proof of concept of detecting iodine fluorescence emission during a SSRT
treatment and is a first step towards in vivo dosimetry in SSRT using X-ray spectroscopy.
The approach in this paper helped us to point out the quantification issues in the
technique. Though sensitive to the material segmentation, the technique proposed here
retrieves a rough estimate of the iodine concentration in the tumor instantaneously. A
range of iodine concentration ranging from 0.1 to 0.8 mg/ml has been retrieved compared
to the 2 mg/ml expected. Improvements of the collimation should enhance the accuracy
of the technique that can become a great added value to the SSRT project in terms of
quality insurance.
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